Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade
| العنوان: | Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade |
|---|---|
| المؤلفون: | Hendrik Tobias Arkenau, Mario Uccello, Stergios Boussios, Michele Moschetta, Martin Forster, Benjamin Kasenda, Anissa McClelland, Gabriel Mak |
| المصدر: | BioMed Research International, Vol 2017 (2017) BioMed Research International |
| بيانات النشر: | Hindawi Limited, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Article Subject, Neutrophils, medicine.drug_class, Programmed Cell Death 1 Receptor, lcsh:Medicine, B7-H1 Antigen, Disease-Free Survival, General Biochemistry, Genetics and Molecular Biology, Tyrosine-kinase inhibitor, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Internal medicine, medicine, Humans, Lymphocyte Count, Lymphocytes, Protein Kinase Inhibitors, Survival rate, Aged, Aged, 80 and over, General Immunology and Microbiology, Performance status, Proportional hazards model, business.industry, lcsh:R, Retrospective cohort study, General Medicine, Middle Aged, Surgery, Blockade, Survival Rate, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, Cohort, Female, business, Research Article |
| الوصف: | Introduction. Baseline neutrophil-to-lymphocyte ratio (NLR) has been repeatedly reported as a significant prognostic factor in advanced cancer patients. We explored whether changes in NLR may predict outcome of advanced cancer patients enrolled into phase 1 trials and treated with PD-1/PD-L1 inhibitors. Patients and Methods. Advanced cancer patients enrolled into phase 1 trials between September 2013 and May 2016 and treated with anti-PD-1/PD-L1 agents were included in this retrospective study. NLR was calculated at baseline and after 2 cycles of treatment. Royal Marsden Hospital (RMH) prognostic score and Eastern Cooperative Group (ECOG) performance status (PS) were determined at baseline. Kaplan-Meier estimation and Cox regression analyses were used to assess the impact of NLR dynamics on PFS. Results. Among the 55 patients eligible, 26 (47%) were treated with anti-PD-L1 monotherapy, 22 (40%) received single agent anti-PD-1, and 7 (13%) were given a tyrosine kinase inhibitor (TKI) plus a PD-1 inhibitor. Neither ECOG PS nor RMH prognostic score was significantly associated with PFS in our cohort, whereas changes in NLR significantly impacted on PFS. Conclusion. Changes in the NLR may be a useful predicting factor in advanced cancer patients treated with anti-PD-1/PD-L1 agents. Further prospective trials are needed to verify these findings. |
| وصف الملف: | text/xhtml |
| اللغة: | English |
| تدمد: | 2314-6141 2314-6133 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9096f4fbe5cae2eaab29d49a2dce6d1Test https://doaj.org/article/70e1ed77a24248f4946abbd7b5b569a6Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....d9096f4fbe5cae2eaab29d49a2dce6d1 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 23146141 23146133 |
|---|